Euclidean Capital LLC
13F Reported Value
ⓘ$392.3M
Holdings
10
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Euclidean Capital LLC disclosed 10 positions worth $392.3M in its Form 13F-HR for Q1 2026. During the quarter the fund opened 0 new positions and exited 2 and a full exit from $SPY. The portfolio is most concentrated in Other (92.5% of disclosed assets). All figures are sourced directly from Euclidean Capital LLC’s Form 13F-HR filing with the SEC under CIK 1825034.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
VANGUARD INTL EQUITY INDEX F
—Quality
$243.6M3,243,484 shVANGUARD INDEX FDS
—Quality
$102.0M520,000 shISHARES TR
—Quality
$17.3M369,600 sh- —
Quality
$12.5M989,410 sh - 11.2
Quality
$7.5M1,573,761 sh - —
Quality
$3.3M2,627,643 sh - 8.9
Quality
$2.8M1,307,858 sh - —
Quality
$2.6M87,696 sh - —
Quality
$703.3K1,015,705 sh - —
Quality
$2.7K170,833 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| VANGUARD INTL EQUITY INDEX F | — | $243.6M | 3,243,484 |
| VANGUARD INDEX FDS | — | $102.0M | 520,000 |
| ISHARES TR | — | $17.3M | 369,600 |
 Oric Pharmaceuticals, Inc.$ORIC | — | $12.5M | 989,410 |
 Foghorn Therapeutics Inc.$FHTX | 11.2 | $7.5M | 1,573,761 |
 PMV Pharmaceuticals, Inc.$PMVP | — | $3.3M | 2,627,643 |
 Alector, Inc.$ALEC | 8.9 | $2.8M | 1,307,858 |
 Surrozen, Inc./DE$SRZN | — | $2.6M | 87,696 |
 Tenaya Therapeutics, Inc.$TNYA | — | $703.3K | 1,015,705 |
| Surrozen, Inc./DE$SRZN | — | $2.7K | 170,833 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Euclidean Capital LLC's 10 positions.
Showing top 10 of 10 holdings.
Sector Allocation
Other
$362.9M
Healthcare
$29.4M
Full Holdings — Euclidean Capital LLC (Q1 2026)
All 10 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | VANGUARD INTL EQUITY INDEX F | $243.6M | 62.1% | +8% | — |
| 2 | — | VANGUARD INDEX FDS | $102.0M | 26.0% | +0% | — |
| 3 | — | ISHARES TR | $17.3M | 4.4% | +0% | — |
| 4 | $ORIC | Oric Pharmaceuticals, Inc. | $12.5M | 3.2% | +0% | — |
| 5 | $FHTX | Foghorn Therapeutics Inc. | $7.5M | 1.9% | +0% | 11.2 |
| 6 | $PMVP | PMV Pharmaceuticals, Inc. | $3.3M | 0.8% | +0% | — |
| 7 | $ALEC | Alector, Inc. | $2.8M | 0.7% | +0% | 8.9 |
| 8 | $SRZN | Surrozen, Inc./DE | $2.6M | 0.7% | +0% | — |
| 9 | $TNYA | Tenaya Therapeutics, Inc. | $703,274 | 0.2% | +0% | — |
| 10 | $SRZN | Surrozen, Inc./DE | $2,733 | 0.0% | +0% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Euclidean Capital LLC including:
Track Euclidean Capital LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Euclidean Capital LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Euclidean Capital LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Euclidean Capital LLC (SEC CIK: 1825034), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Euclidean Capital LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.